Kornimate/medical-research-clean huggingface dataset:
neuromodulation of motion illusions (vection)

Conditions: Healthy

Summary: virtual reality systems or simulators are more and more frequently used in the field of learning but also in motor rehabilitation. one of the key points of the success of these systems is the experience of "presence" which is associated with the capacity of these technologies to develop in the observer, who is static, the sensation of moving in the virtual environment (vection). however, the simulation generates a sensory conflict (an optical flow specifying self-motion and vestibular stimuli specifying body immobility). this conflict influences the temporal characteristics of the vection and consequently modifies the way users act in their virtual environment. thus, contrary to a real situation, vection does not occur instantaneously with the appearance of a visual movement. moreover, the visual stimulus often generates alternating periods of perception of movement of the environment and of oneself (bistable perception) which can lead to "simulator sickness", a disabling situation for the user. thus, as vection is an essential element to allow an "optimal transfer of learning" from the simulator to reality, it may be important to promote its emergence while limiting its bistability. the aim of this project is to study the inhibitory or facilitative modulation of the emergence of the vection phenomenon by the use of non-invasive cortical stimulation techniques (transcranial electrical stimulation (tes), transcranial alternative current stimulation (tacs), and repeated transcranial magnetic stimulation (rtms)).


Eligibility criteria:
inclusion criteria: * healthy subjects aged 18 to 40 years * right-handed subjects * signed informed consent, * medical examination performed prior to participation in the research, * affiliation to or beneficiary of a social security plan exclusion criteria: * contraindications (ci) to the practice of mri, eeg, tms \& tes * existence of a severe general condition: cardiac, respiratory, hematological, renal, hepatic, cancerous, * regular use of anxiolytics, sedatives, antidepressants, neuroleptics, * characterized psychiatric pathology, * ingestion of alcohol before the examination, * pregnant, parturient or breastfeeding women * person deprived of liberty by judicial or administrative decision, person under a legal protection measure (under guardianship or curators) * participation in other interventional research protocols in progress with an exclusion period or in the previous week subject who would receive more than 4500 euros of compensation due to his participation in other research involving the human person in the 12 months preceding this study

Keywords: vection neuromodulation rtms tacs
modeling genotype and other factors to enhance the safety of coumadin prescribing

Conditions: Atrial Fibrillation; Deep Venous Thrombosis; Heart Valve Replacement; Pulmonary Embolism

Summary: the study goal is to conduct a randomized controlled trial to compare safety and accuracy of dosing based on clinical information including the clinical reason for your taking coumadin, your age, gender, your body surface area, and other medical conditions you may have with dosing estimated by a dosing calculator which adjusts for factors affecting coumadin dosing variability including genotypes for genes important in coumadin metabolism and response. the hypothesis to be tested by this trial states that:when compared to patients managed with a best practices standard-of-care coumadin dosing regimen, patients randomized to coumadin dosing based on genetically programmed metabolic capacity and other known clinical and environmental factors affecting dose will: 1)show reduced risk of adverse events (using surrogate measures of such events); and 2)more rapidly achieve coumadin dosing.

the study goal is to conduct a randomized controlled trial to compare safety and accuracy of dosing based on clinical information including clinical reason for taking coumadin, your age, gender, your body surface area, and other medical conditions you may have and dosing with dosing estimated by a dosing calculator which adjusts for factors affecting coumadin dosing variability including genotypes for genes important in coumadin metabolism and response. the hypothesis to be tested by this trial states that:when compared to patients managed with a best practices standard-of-care coumadin dosing regimen, patients randomized to coumadin dosing based on genetically programmed metabolic capacity and other known clinical and environmental factors affecting dose will: 1)show reduced risk of adverse events (using surrogate measures of such events); and 2)more rapidly achieve coumadin dosing

Eligibility criteria:
inclusion criteria: * caucasian male and female patients(including hispanic white) greater than or equal to 40 years of age; * patients initiating coumadin therapy without a documented history of stabilized dose of coumadin therapy; * target inr of 2 to 3.5; * women of childbearing potential must use an effective method of birth control(e.g. condom,oral contraceptives, indwelling intrauterine device, abstinence. exclusion criteria: * age less than 40 years; * patients of known native american, asian, or african descent; * patients with thrombocytopenia(platelet count\<50x10 cells/ml); * patient has previously received coumadin and information on dosing of the patient is known at time of restarting coumadin; * patients with severe to moderate hepatic insufficiency (ast or alt less than 2x the upper limit of normal; * clinical contraindication for coumadin therapy; * female patients with a positive pregnancy test or women who are breastfeeding
intraventricular hemorrhage and post hemorrhagic ventricular dilation: natural course, treatment, and outcome

Conditions: Intraventricular Hemorrhage; Premature Infants

Summary: intraventricular hemorrhage and its resultant post-hemorrhagic hydrocephalus are significant risk factors for the development of neurodevelopmental delays in preterm infants. the purpose of this study is to determine 1) the incidence of progressive post-hemorrhagic ventricular dilatation (phvd) in infants with severe intraventricular hemorrhage (ivh), 2) the effect of ventricular dilatation on brain status (cerebral oxygenation, electrical activity, and biomarkers of cerebral damage and repair), and 3) if using ventricular measurements, derived from cranial ultrasound to guide removal of cerebral-spinal fluid through an omaya reservoir, will help resolve ventricular dilatation and decrease the need for ventriculo-peritoneal (vp) shunt insertion. the hypothesis of this research project is that, by using ventricular measurements to guide the frequency of csf removal, the rate of vp shunt insertion will be decreased in preterm infants with severe ivh and phvd. the investigators further hypothesize that cerebral injury, as measured by cerebrospinal fluid (csf) concentration of biomarkers of neuronal and glial damage and inflammation, will decrease over time with resolution of phvd.

when an infant has severe ivh noted on cranial ultrasound, s(he) will receive weekly ultrasounds to evaluate progression of ventricular dilatation (standard of care). after the infant is enrolled in this study, near-infrared spectroscopy (nirs) and amplitude integrated electroencephalogram (aeeg) will be performed 1-2 times per week. after omaya reservoir insertion, ventricular dimensions, based on weekly (standard of care) cranial ultrasounds, will determine frequency of csf removal. nirs and aeeg will continue 1-2 times per week to coincide with csf removal. in addition, 1-2 times per week aliquots of csf will be stored for evaluation of biomarkers. we will evaluate the impact of ivh and phvd over time on cerebral oxygenation (nirs) and cortical electrical activity (aegg) starting at the time of identification of ivh and correlate these measurements to ventricular dimensions. if an omaya reservoir is required to control phvd, we will use ventricular dimensions to guide the frequency of csf removal and continue to evaluate brain status by measuring cerebral oxygenation (nirs) and cortical electrical activity (aegg).

Eligibility criteria:
inclusion criteria: * severe ivh * receiving weekly head ultrasounds for monitoring exclusion criteria: * no or minimal ivh

Keywords: omaya reservoirs cerebral oxygenation vp shunt ivh post hemorrhagic ventricular dilation (pvhd)
prospective multicentre phase-iv clinical trial of olaparib in indian patients with ovarian and metastatic breast cancer

Conditions: Ovarian Cancer; Breast Cancer

Summary: a prospective, multicentre, phase-iv clinical trial of olaparib in indian patients with platinum sensitive relapsed ovarian cancer who are in complete or partial response following platinum based chemotherapy and metastatic breast cancer with germline brca (breast cancer gene) 1/2 mutation

a prospective, multicentre, phase-iv clinical trial of olaparib in indian patients with platinum sensitive relapsed ovarian cancer who are in complete or partial response following platinum based chemotherapy and metastatic breast cancer with germline brca(breast cancer gene)1/2 mutation as per recommendation from dcgi(drug controller general of of india), the current phase-iv study is planned with the aim to assess the safety in indian subjects receiving olaparib as per the approved label indications in india in accordance with the requirements of the health authorities of india. this study attempts to descriptively elucidate the safety of olaparib in indian subjects receiving olaparib as per the indian regulatory approved indications in india. the data obtained from the present study will help to understand the safety profile of olaparib in indian patients.

Eligibility criteria:
inclusion criteria: 1. provision of signed and dated, written informed consent form prior to any mandatory study specific procedures.. 2. female subjects with ≥ 18 years of age 3. subjects receiving olaparib for the following indications in ovarian cancer: for the maintenance treatment of adult subjects with recurrent epithelial ovarian, fallopian tube or primary peritoneal cancer, who are in a complete or partial response to platinum-based chemotherapy 4. subjects receiving olaparib for the following indication in breast cancer: in subjects with deleterious or suspected deleterious gbrcam, her2-negative metastatic breast cancer who have previously been treated with chemotherapy in the neoadjuvant, adjuvant or metastatic setting. subjects with hr-positive breast cancer should have been treated with a prior endocrine therapy or be considered inappropriate for endocrine treatment exclusion criteria: 1. patients with either the history of hypersensitivity to excipients of the study drug or to drugs with a similar chemical structure or class to the study drug. 2. pregnant and/or lactating women. 3. patients with a previously or currently diagnosed mds/ aml or pneumonitis. 4. patients who have not recovered sufficiently from prior surgery or anticancer treatment. 5. patients who have known history of hepatitis b or hepatitis c 6. patients with active infection such as tb. 7. participation in another clinical study with a study drug administered in the last 3 months

Keywords: ovarian cancer; breast cancer, olaparib
foley vs propess for induction of labor in women with term prom : mode of delivery, maternal and fetal outcomes

Conditions: Premature Rupture of Membranes at Term; Mode of Delivery

Summary: premature rupture of membranes at term is a rupture that occurs at term (\>37sa) before the start of labor. it complicates 5 to 10% of pregnancies and 6 to 22% of term pregnancies. althought some studies support efficacy of the foley catheter for cervical ripening at term in induction of labor with intact membranes, it has not been well studied in women with premature rupture of membranes at term. the aim of this retrospective study at the montpellier university hospital is to evaluate the effect of the foley catheter compared to propess in women with premature rupture of membranes at term, on the induction of labor and the maternal and fetal complications.


Eligibility criteria:
inclusion criteria: * singleton pregnancy \>37 weeks of gestation * premature rupture of membranes * cephalic presentation * unfavorable cervix (bishop \<7) * no contraindication of induction methods exclusion criteria: * multiple gestation * prom with spontaneous labor * induction of labor with both methods * previous cesarean section * unexplained metrorrhagia / placenta praaevia * suspected intraamniotic infection * herpes simplex virus * human immunodeficiency virus * any contraindication to vaginal delivery * latex allergy

Keywords: complications and outcomes maternal and neonatal induction of labor prostaglandins foley catheter
therapeutic strategy guided by pet-tdm for patients with seminoma

Conditions: Seminoma

Summary: the purpose of the study is to evaluate the ration of patients getting an lighten therapeutic strategy after 18f-fluoro-désoxyglucose positron emission tomography (pet-tdm) in grade i (cohort 1) or metastatic (cohort 2) seminoma


Eligibility criteria:
inclusion criteria shared: * histologically proved seminoma after orchiectomy * primary testicular or retroperitoneal * normal alpha-fetoprotein before and after orchiectomy * no prior treatment with radiotherapy or chemotherapy * age \>= 18 years * ecog 0 to 2 * pnn \>= 1500, platelets \>= 100 000, bilirubin \<= the upper limit nromale * asat (sgot) and alat (sgpt) \<= 1,5 x the upper limit nromale * serum creatinine \ 60 ml / min) * information and signed informed consent before inclusion in the study * patient affiliated to a social security specific inclusion criteria for cohort 1: * grade i specific inclusion criteria for cohort 2: * grade iib (retroperitoneal adenopathy diameter between 2 cm and 5 cm, regardless of the ldh) * grade iic (retroperitoneal adenopathy diameter higher than 5 cm, regardless of the ldh) * grade iii of good prognosis (supradiaphragmatic reach with ganglionic metastasis and ldh \< 2 times normal limit and/or supradiaphragmatic reach with pulmonary metastasis and ldh \< 2 times normal limit) either at initial diagnosis or relapse of a grade i seminoma) * pet-tdm positive (pathological fixation on metastatic lesions) exclusion criteria shared: * patient infected by hiv, hepatitis b or c * history, within 5 years, of cancer other than seminoma, except for treated skin cancer (basal cell) . * visceral metastasis * cerebral metastasis * any physical or mental condition incompatible with the treatment (to the investigator discretion) * uncontrolled or severe cardiovascular pathology * uncontrolled or severe hepatic pathology * persons deprived of liberty or under guardianship * unable to undergo medical monitoring due to geographical, social or psychological reasons
pulmonary fibrosis lung sounds study

Conditions: Pulmonary Fibrosis; Healthy

Summary: the goal of this observational study is to test whether it is possible to detect particular lung sounds that are unique to patients with the lung disease pulmonary fibrosis and whether any such sounds could be analysed using machine learning to make diagnosing disease easier. participants will have a sound detection device placed in different locations on the chest and audio sounds will be recorded for analysis. researchers will compare audio recordings from clinically diagnosed patients with recordings from healthy controls of a similar age to see whether the sounds are sufficiently different within that age group.

this is a study of chest audio recordings obtained using a sound enhancer, in this case a bluetooth device, combined with intelligent computer-processing and analysis. it is being carried out amongst pulmonary fibrosis patients and healthy controls of a similar age, with the aim to improve diagnosis of pulmonary fibrosis and remote monitoring of disease progression. expert respiratory doctors gain important insights about the health of a patient's lungs by listening to the chest with a stethoscope. currently, there are insufficient respiratory experts and specialist equipment to meet the patient demand, leading to delays in diagnosis and treatment and a shortage of specialist care following diagnosis. in this study the investigators are aiming to make that specialist practice much more available by recording lung sounds and developing software to do the intelligent analysis. initial tests with publicly available recordings of expertly diagnosed respiratory sounds have shown that different lung diseases can be detected with a very high degree of accuracy using new software. here the investigators want to test that software with a cost-effective digital sound device in a clinical setting. the aim is for respiratory diseases to be diagnosed quickly and easily and also, in future, for patients to be offered the option to monitor how well they are after diagnosis in their own home.

Eligibility criteria:
inclusion criteria * able to understand what the study involves * able and willing to give informed consent for patients: * age≥60 (pf affects adults, with the majority of age≥60) * a diagnosis of progressive pulmonary fibrosis (to include all diagnosed interstitial lung disease (ild) patients presenting at the ild clinic) for healthy controls: * age≥60 (to ensure that age of controls is similar to that of patients so that younger age does not bias results) * no known lung disease exclusion criteria * unable to understand what the study involves * unwilling or unable to give consent * age\<60 (to ensure that age does not confound results and cases and controls are of similar age, since the majority of pulmonary fibrosis patients are of age≥60)
endodontic microsurgery with the use of l-prf and an occlusive membrane: a randomized controlled clinical trial

Conditions: Periapical Periodontitis

Summary: this study evaluates the effect of leucocyte and platelet rich fibrin (l-prf) during endodontic microsurgery (ems) on patient's post-operative comfort and periapical bone healing. also the influence of an occlusive membrane barrier in ems on the periapical bone healing will be studied. the trial design is an open randomized controlled clinical trial with a 2x2 factorial design. half of the participants will receive ems with l-prf (experimental group), the other half without (control group). the control and experimental group will be divided in 2 subsequent groups: half of the participants will receive an occlusive membrane during ems, the other half not.


Eligibility criteria:
inclusion criteria: * provision of informed consent * patients in need of an ems * ems is the only option to cure the periapical lesion exclusion criteria: * unlikely to be able to comply with the study procedures, as judged by the investigator * orthograde endodontic (re)treatment is indicated * known or suspected current malignancy * history of chemotherapy within 5 years prior to study * history of radiation in the head and neck region * history of other metabolic bone diseases * history of bleeding disorders * hiv disease

Keywords: platelets
lithium for low-grade neuroendocrine tumors

Conditions: Neuroendocrine Tumors

Summary: the purpose of this study is to learn more about the effectiveness and side effects of lithium treatment for subjects with low-grade neuroendocrine tumors.

lithium 300mg by mouth, three times daily, escalating to a lithium level of 0.8-1.0; continue until progressive disease/unacceptable toxicity;evaluate q 8 weeks.

Eligibility criteria:
inclusion criteria: * must have histologically confirmed metastatic low-grade neuroendocrine neoplasms. small cell lung cancers, paragangliomas and pheochromocytomas are excluded. pathologic diagnosis must be confirmed at the university of wisconsin carbone cancer center (uwccc). grading must be confirmed by pathologic review performed at uwccc. * must have measurable disease * must have radiographic evidence of disease progression following any prior systemic therapy, chemoembolization, bland embolization, surgery, or observation. * must be ≥ 4 weeks from the completion of major surgery, chemotherapy, or other systemic therapy or local liver therapy to study registration * must be ≥ 3 weeks from the completion of radiation therapy to study registration * the following laboratory values are to be obtained within 14 days prior to registration: absolute neutrophils count (anc) ≥ 1000/mm3; platelets ≥ 75,000/mm3; hemoglobin ≥ 8.0 g/dl; total bilirubin less than or equal 2.0 x the upper limit of normal (uln); ast less than or equal to 3 x uln or less than or equal 5 x uln if liver metastases are present; creatinine less than or equal uln; serum sodium within normal limits * ps = 0-2 * capable of understanding the investigational nature, potential risks and benefits fo the study and able to provide valid informed consent. * must have available tissue specimens to be analyzed for pathologic confirmation. * age ≥ 18 years. * women must not be pregnant or lactating. * women of childbearing potential and sexually active males are required to use an accepted and effective method of contraception. * patients must not have known history of allergic reactions or adverse reactions to lithium or derivatives. * patients are not allowed to be on concurrent chemotherapy or radiation therapy. * patients are excluded if they have any of the following: gastrointestinal tract disease resulting in an inability to take oral medication (i.e. ulcerative disease, uncontrolled nausea, vomiting, diarrhea, bowel obstruction, or inability to swallow the tablets. history of hypothyroid disease significant, active cardiac disease * patients must not be taking the following medications: diuretics, ace inhibitors, nsaids (except aspirin or sulindac), neuroleptics, tetracycline, cox2 (cyclooxygenase-2) inhibitors, citalopram, clovoxamine, escitalopram, femoxetine, fluoxetine, fluvoxamine, paroxatine, sertraline, and zimeldine. * must be willing to undergo a tumor biopsy pre and post therapy. * patients with a concurrent malignancy are allowed on study as long as the patient is not undergoing active treatment for their disease. * patients already taking lithium for any reason are not allowed on study.

Keywords: low-grade neuroendocrine tumors lithium
group cognitive behavioral therapy to treat depression in an epilepsy clinic setting

Conditions: Epilepsy; Depressive Disorder

Summary: this study involves a form of group therapy called cognitive behavioral therapy or cbt for depressed patients with epilepsy. the cbt groups will be tailored for an epilepsy clinic population. there are 12 sessions of therapy in the study held once a week for 12 weeks.

depression is frequent in pwe and often missed for unclear reasons. busy neurology clinics and their overworked physicians often lack psychiatric backup that may make inquiring about psychological issues problematic. in the psychiatric community, awareness of the need for depression intervention in the primary care clinic has been recognized for many years and several treatment models exist. this study will attempt to use one such model, i.e. cognitive-behavioral therapy (cbt) using a group format and tailoring its use for an epilepsy clinic population.

Eligibility criteria:
inclusion criteria::- patients will be screened with the beck depression inventory. those reaching the positive cut-off score of 11 (indicating at least a mild depression) will be entered into the study. patients entered on antidepressants will be held at a stable dosage. anti-epileptic drugs will also be maintained on the same dosage at entry into the study when possible clinically, after consultation with their neurologist. exclusion criteria:- patients will be excluded if there is any active serious medical conditions, standard score\<70 as assessed via the wide range achievement test, psychotic or substance abuse issues, those who are unable to maintain a stable dose of medications for the duration of study.